Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Glenmark Pharmaceuticals

Next Previous
Search
Drug Profile

Trastuzumab biosimilar - Glenmark Pharmaceuticals

Alternative Names: GBR-200

Latest Information Update: 15 Jan 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Breast cancer

Most Recent Events

  • 21 Oct 2020 Trastuzumab biosimilar is still in phase III trials for Breast cancer in India (CTRI/2017/02/007892)
  • 29 Aug 2017 Phase-III clinical trials in Breast cancer (Late-stage disease, Metastatic disease, Combination therapy) in India (IV) (CTRI2017-02-007892)
  • 08 Mar 2017 Glenmark Pharmaceuticals plans a phase III trial for Breast cancer (Combination therapy, Metastatic disease, Late-stage disease) in India (CTRI2017-02-007892)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top